MARSHALL WACE, LLP

Position in PTCT — Ptc Therapeutics, Inc.

CIK 1318757 LONDON, X0

Position in PTCT

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$31,383,266

+$12,564,481 QoQ

Shares Held

460,638

+85.9% QoQ

Ownership

0.555%

of shares outstanding

% of Portfolio

0.05%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2020

13 quarters on record

Voting authority Sole 0.ToString("F0")% Shared 100.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

MARSHALL WACE, LLP holds $2,766,756,129 across 280 Biotechnology names. PTCT ranks #20 (1.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	1,099,318	$363,731,344
2	VRTX	Vertex Pharmaceuticals Inc / Ma	317,058	$141,579,078
3	INCY	Incyte Corp	1,253,138	$117,945,347
4	RPRX	Royalty Pharma plc	2,120,692	$101,729,594
5	RCUS	Arcus Biosciences, Inc.	3,761,437	$81,247,039
6	PTGX	Protagonist Therapeutics, Inc	628,075	$66,199,104
7	ROIV	Roivant Sciences Ltd.	2,246,943	$62,240,320
8	COGT	Cogent Biosciences, Inc.	1,600,168	$61,590,466

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$31,383,266	460,638	+85.9%	Shares	Other	2026-05-15
2025-12-31	$18,818,785	247,746	+57.1%	Shares	Other	2026-02-13
2025-09-30	$9,680,441	157,739	-70.7%	Shares	Other	2025-11-13
2025-06-30	$26,264,978	537,776	-27.4%	Shares	Other	2025-08-13
2025-03-31	$37,761,461	741,002	+312.4%	Shares	Other	2025-05-15
2024-06-30	$5,494,583	179,679	+708.7%	Shares	Other	2024-08-14
2024-03-31	$646,350	22,219	+259.4%	Shares	Other	2024-05-15
2023-06-30	$251,421	6,182	+2.3%	Shares	Other	2023-08-14
2021-12-31	$240,652	6,042	0.0%	Shares	Other	2022-02-14
2021-09-30	$224,822	6,042	-85.7%	Shares	Sole	2021-11-15
2021-03-31	$2,000,868	42,257	+41.8%	Shares	Sole	2021-05-17
2020-09-30	$1,393,150	29,800	-13.8%	Shares	Sole	2020-11-16
2020-06-30	$1,754,386	34,576	—	Shares	Sole	2020-08-13
No filing history on record for this holder in this stock.